Investors may be lulled into thinking that stocks they own or study in the cannabis space are insulated from what’s happening in the broader market. But that’s simply not true, and violates one of the oldest maxims in investing: Don’t fight the tape.
Author Archives: Ryan Barnes
Ownership in the Medicine Man Denver stores—there are two now, one near the airport in Denver and one in Aurora—is not actually what is being pitched to investors in the S-1 from Medicine Man Technologies. The business of Medicine Man Technologies is actually consulting, but its model and outlook are inexorably tied to the highly successful cultivator and retailer you may have seen on MSNBC’s “Pot Barons” TV series.
It has been a bit of a dry spell for decent IPOs in the cannabis space. But the rains have come down with the initial public offering of Devon, Pennsylvania-based Zynerba Pharmaceuticals (NASDAQ: ZYNE).
It has been a couple of months since MassRoots (OTCQB: MSRT) became a publicly-traded company. Since that time, the company has struggled to see its share price break above the original offering price.
MyDx’s hardware/software ecosystem has a very easy value proposition to dish out: simple, instant testing of solids, liquids and gases to measure their positive attributes, and whether there’s any pesticides or other no-gooders in your food, water and air.
The attractiveness of an ETF that could lower the volatility and risk of making an investment into a single cannabis stock is quite evident. But is it feasible?
On June 24, 2015, it was announced that two of the biggest brands in the burgeoning Canadian cannabis market are about be under one roof. Tweed Marijuana Inc. (TSXV: TWD) has agreed to acquire all the outstanding shares of Bedrocan Canada (TSXV: BED).
The evolution of the cannabis market in Canada continues to be a crucial case study. There is a lot we can learn about how business models are taking shape and the headwinds being faced in the legalized medical environment that the Canadian MMPR provides.
On May 29, 2015, Marijuana Business Daily reported that it had viewed a memo from insurance behemoth Lloyd’s of London, wherein it directs its underwriters not to write or renew existing policies to cannabis-based companies until the plant is legal on the federal level.
Always on the lookout for ways investors are participating the cannabis space, today we are taking a look at a publicly traded company that, on the surface, offers a unique access point.
Last Wednesday, two pain specialists that were top subscribers of Insys Therapeutics’ (NASDAQ: INSY) leading prescription therapy Subsys were arrested, as part of a year-long operation by the DEA.
Oxis Biotech, a subsidiary of Oxis International (OTCQB: OXIS), recently filed a notification to shareholders and the SEC that the company would be entering into a reverse split of not less than 1-50 shares and not more than 1-250 shares.
If you can forgive the rather liberal stretching of the analogy here, there are a lot of correlations between cannabis as an industry and this key stage of human development.
Would you like to invest in Uber? Or how about Airbnb? Well it turns out that you can’t. If you’re a regular Joe or Jane investor, there are no shares to buy for either company, or for companies like Pinterest and SpaceX.
In the past few weeks we have seen some massive volatility in the most active cannabis stocks. At the same time we have seen broad market indexes like the NASDAQ and the S&P 500 hit new record highs, begging the question of whether the cannabis stocks are just following general momentum.
Every industry is only as strong as the connection between the capital needed to grow and maintain it, and the companies themselves, who allocate that capital to expand new markets, lower costs, add services and improve product offerings.
MassRoots, which will begin trading on or around April 9, 2015, under the ticker MSRT, is set to be the first public cannabis company with a revenue model and a customer acquisition strategy built entirely around social media platforms.
Considering an investment in the cannabis industry? Consider this a brief starting guide to making responsible choices. It may help you determine if considering an investment in the cannabis industry is right for you.
The recent proposal of the CARERS Act and statements from President Barack Obama have spawned a lot of interest and momentum in cannabis stocks, and it is especially noticeable after such a languid period last year.
Today we’ll be looking under the hood of two more companies, but before we do it’s worth spending a moment to take note of how the cannabis industry could be massively reframed as a result of recent news out of Washington, D.C.
CanopyBoulder wants to support the responsible growth of the cannabis industry by mentoring young companies as they get their businesses off the ground.
There are many early-stage companies with an eye on cannabis that are entering the publicly-traded space these days. We wanted to give you a brief overview of some of the companies that are likely to offer public securities for the first time in 2015.
It has been a noteworthy past few days in the realm of investors’ rights. Two different stories that may seem completely unrelated are sewn with some of the same thread, especially for investors that are actively looking at the cannabis space.
Investing “in the plant” remains a road that can only be traveled by a select few in the United States. But in Canada, it is a whole different story.
If you think the marriage of a business accelerator and the fastest-growing industry in America seems like a slam dunk, you’re right.
By far one of the most interesting trial balloons the cannabis industry will ever see is about to get floated in the form of medical marijuana in Nevada, and specifically in the den of iniquity itself, Las Vegas.
Denver-based MassRoots is a distinct first mover into what could become a valuable corner of the social media ecosystem—a community by, of, and for cannabis enthusiasts.
The early leaders in market cap (the total value of publicly-traded equity) in a expanding industry like cannabis can tell us a lot. These companies have a lot of advantages by being on this perch, but also some responsibilities.
Every good business idea starts with an unmet need. Josh Gordon, CEO and founder of The Bureau, sees an unmet need for cannabis consumers to transport, store and present their product with class.
As founder and managing partner of Dutchess Capital, a Boston-based venture capital firm, Douglas Leighton is no stranger to burgeoning industries.
Ebbu specializes in creating healthier, safer cannabis-based medicinal and recreational products.
The Bureau wholesales packing solutions to dispensaries, including California medical marijuana dispensary Harborside Health Center, as well as direct to consumers via its new website, thebureau.nyc.
Have you ever heard of ebbu before? Until a week ago, I hadn’t either, and I make it my business to keep my ear pretty low to the ground on such things.
Stocks in the highly volatile cannabis space continue to slowly evaporate away all the immense gains they saw early in 2014. This is not unexpected, as things were way too overheated in the spring.
Estimates vary greatly, but the total size of legal, cannabis-centric industries is somewhere between $2 billion and much, much higher.
Whether you are already an active investor in marijuana-based industries or just taking notes from the sidelines, chances are you don’t need me to tell you that the business is becoming fast and furious.